Home›Companies›Biotech & Pharma›VETmAb BIO

Vetmab Biosciences, Inc.

Develops antibody treatments for veterinarians caring for dogs and cats.

Updated Nov 9, 2026·Latest SEC filing Sep 29, 2026·Suggest an edit

About VETmAb BIO

VETmAb BIO is a private company based in San Diego, California, incorporated in 2022 in Delaware. It has reported $14,015,012 raised in four offerings on Form D since June 2022. Its chief executive is Denise Bevers.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 17, 2026Sep 29, 2026$11,439,990of $11.9M target30$381KEquityRule 506(b)Form D ↗
Nov 21, 2023Dec 5, 2023amended Dec 5, 2023$575,000of $5.0M target5$115KEquity, OptionsRule 506(b)Form D/A ↗1 earlier filing
Aug 9, 2022Aug 22, 2022$2,000,000fully sold28$71,429EquityRule 506(b)Form D ↗
Jul 8, 2022Jun 10, 2022amended Jul 19, 2022$22fully sold42$1EquityRule 506(b)Form D/A ↗1 earlier filing
Total, four offerings$14,015,012

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on VETmAb BIO's Form D filed Sep 29, 2026.

Denise Bevers
Denise Bevers
Co-founder, President & CEO, Board Member
Also a director at Hilltop Biosciences.
Richard Chin
Richard Chin
Co-founder, Chair of the Board
Also a director at Bio Usawa.
Hangjun Zhan
Hangjun Zhan
Director
NA
Neeraj Agrawal
Director
Also a director at EndoQuest Robotics, Kustomer and Pendo.io and an executive officer at Battery Ventures.

Sources

  1. SECVetmab Biosciences, Inc. Form D, filed Dec 5, 2023
  2. SECVetmab Biosciences, Inc. Form D, filed Jun 10, 2022
  3. SECVetmab Biosciences, Inc. filing history
  4. CompanyPrivacy policy
  5. CompanyAbout VETmAb BIO